Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system designed to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which are comprised of sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Period	Debt/Equity
2021-12-31	0.10
2022-03-31	0.91
2022-12-31	0.11
2023-03-31	1.67
2023-12-31	0.15
2024-12-31	0.16

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NAUT	$3.17	+1.60%	0.27M
3
4
5

Nautilus Biotechnology Inc. (NAUT) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Nautilus Biotechnology Inc. Data in Excel

More NAUT Financial Data